Phan Angela N, Terry Garth E
University of Washington School of Medicine, Seattle, WA, United States.
Departments of Psychiatry and Behavioral Sciences, and Radiology, University of Washington School of Medicine, Seattle, WA, United States.
Front Psychiatry. 2023 Jun 26;14:1144276. doi: 10.3389/fpsyt.2023.1144276. eCollection 2023.
Cannabis use disorder (CUD) is prevalent in ~2-5% of adults in the United States and is anticipated to increase as restrictions to cannabis decrease and tetrahydrocannabinol (THC) content in cannabis products increase. No FDA-approved medications for CUD are currently available, despite trials of dozens of re-purposed and novel drugs. Psychedelics have garnered interest as a therapeutic class in other substance use disorders, and self-report surveys suggest they may result in positive outcomes for CUD. Herein, we review the existing literature pertaining to psychedelic use in persons with or at risk for CUD and consider the potential rationale underpinning psychedelics as a treatment for CUD.
A systematic search was performed in several databases. Inclusion criteria were primary research reporting use of psychedelics or related substances and CUD for treatment in human subjects. Exclusion criteria were results including psychedelics or related substances without changes in cannabis use or risks associated with CUD.
Three hundred and five unique results were returned. One article was identified using the non-classical psychedelic ketamine in CUD; three articles were identified as topically relevant based on their secondary data or consideration of mechanism. Additional articles were reviewed for purposes of background, review of safety considerations, and formulating rationale.
Limited data and reporting are available on the use of psychedelics in persons with CUD, and more research is needed given the anticipated increase in CUD incidence and increasing interest in psychedelic use. While psychedelics, broadly, have a high therapeutic index with infrequent serious adverse effects, particular adverse effects at risk in the CUD population, such as psychosis and cardiovascular events, should be considered. Possible mechanisms by which psychedelics have therapeutic potential in CUD are explored.
大麻使用障碍(CUD)在美国约2%-5%的成年人中普遍存在,并且随着大麻限制的减少和大麻产品中四氢大麻酚(THC)含量的增加,预计其发病率还会上升。尽管对数十种重新利用和新型药物进行了试验,但目前尚无美国食品药品监督管理局(FDA)批准用于治疗CUD的药物。迷幻药作为一类治疗其他物质使用障碍的药物已引起关注,自我报告调查表明它们可能对CUD产生积极效果。在此,我们回顾了有关迷幻药在患有CUD或有患CUD风险的人群中使用的现有文献,并探讨了迷幻药作为CUD治疗方法的潜在理论依据。
在多个数据库中进行了系统检索。纳入标准为报告迷幻药或相关物质用于人类受试者治疗CUD的原发性研究。排除标准为结果中包括迷幻药或相关物质但大麻使用无变化或与CUD无关的风险。
共返回305条独特结果。其中一篇文章使用非经典迷幻药氯胺酮治疗CUD;三篇文章因其二级数据或机制考虑被确定为具有局部相关性。还对其他文章进行了回顾,以获取背景信息、安全性考虑的综述并阐述理论依据。
关于迷幻药在CUD患者中的使用,现有数据和报告有限,鉴于CUD发病率预计会上升以及对迷幻药使用的兴趣增加,需要更多的研究。虽然总体而言,迷幻药具有较高的治疗指数,严重不良反应较少,但应考虑CUD人群中存在风险的特定不良反应,如精神病和心血管事件。本文还探讨了迷幻药在CUD中具有治疗潜力的可能机制。